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risks of cancer, such as hepatocarcinoma. Although Picrorrhiza kurroa has shown activity against
hepatocarcinogenesis, its mechanism of action is poorly understood, further the anticancer activity
of iridoid glycosides present in this plant has not been tested so far.
Aim of the study: Here, MCF-7 cell lines (Human breast cancer) were used to test whetherP. kurroa
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50 D. Rathee et al.exerts the anti-invasion activity via down-regulation of the expression of matrix metalloproteinases
(MMPs). MMPs play an important role in solid tumor invasion and migration.
Materials and methods: The activity and expression of gelatinases (MMP-2 and MMP-9) and col-
lagenases (MMP-1 and MMP-13), protein, and mRNA were detected by gelatin zymography, and
RT-PCR. The migratory and invasive capacities of MCF-7 cell lines were measured by the wound
scratch migration assay. The preliminary cytotoxicity testing was done by MTT assay and propidi-
um iodide staining. Further the inhibition of inﬂammatory mediators was also done by quantiﬁca-
tion of nitrite inﬂammatory mediators.
Results: The study showed that PE and its isolated iridoids glycosides PS, KS, and KT exhibited
considerable cytotoxic potential in a dose-dependent manner. Further PE, PS, KS, and KT inhib-
ited MCF-7 cell invasion and migration, and decreased MMP-2, 9 and MMP-1, 13 activities.
Furthermore, PS, KS, and KT reduced MMPs expression at protein and mRNA levels, and sup-
pression of the inﬂammatory mediators was also exhibited.
Conclusions: Our results suggest that PS, KS, and KT may be the valuable anti-invasive drug
candidates for cancer therapy by suppressing Collagenases and Gelatinases. PS, KS, and KT
showed good results in comparison with PE. PS and KS exhibit almost comparable down regula-
tion while KT exhibited maximum suppression of invasion, migration, and expression of MMPs.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Based on the knowledge of cancer biology, it is clear that, once
cancer cells have spread and formed secondary masses (metas-
tases); cancers are largely incurable despite the progress in
medicine. Two basic principles govern this problem: First, tu-
mors are biologically heterogeneous and contain subpopula-
tions of cancer cells with different properties, and stroma
cells. Second, the metastatic process is a cascade of events that
depend on both tumor cell properties and the microenviron-
ment. A signiﬁcant amount of evidence is accumulating that
favors the notion that not only cancer cells, but also host cells
may be useful therapeutic targets for the treatment of cancer
patients (Joyce, 2005; Liotta and Kohn, 2001; De Wever and
Mareel, 2002, 2003; Bhowmick et al., 2004; Desmoulie`re
et al., 2004). Examples of key therapeutic targets include over
expression of growth factor receptors and their signaling path-
ways (Bange et al., 2001; Colomer et al., 2001; Dolle´ et al.,
2004), angiogenic factors (Dredge et al., 2003; Ziche et al.,
2004), MMPs (matrix metalloproteinase’s) (Egeblad and
Werb, 2002; Yana and Seiki, 2002), and integrin receptors
(Joyce, 2005; Guo and Giancotti, 2004; Xiao et al., 2004).
Metastasis is a characteristic of highly malignant cancers with
poor clinical outcome. Malignant tumor progression depends
upon the capacity to invade, metastasize, and promote the
angiogenic host response. One critical characteristic that
metastasis cancer cells have acquired is the ability to dissolve
basement membranes and the extracellular matrix (ECM).
This degradative process is mediated largely by MMPs
(Forrbes et al., 2003), which are a large family of at least 20
zinc-dependent neutral endopeptidases that together can de-
grade all known components of ECM (Parmo-Cabanas
et al., 2006). Previous studies have shown the expression and
activity of MMPs to be linked to an advanced stage of breast
cancer, increased invasion of tumor cells, and building of met-
astatic formations (Duffy et al., 2000). Various identiﬁed
MMPs-1, 2, 8, 9, 10, 11, 12, 13, 15, 19, 23, 24, 27, and 28 shows
a stronger expression in breast cancer tissue compared to nor-
mal breast tissue and could thus seem to be associated with
breast cancer development. Hence, all fourteen MMPs are can-
didates for future functional analyses and potential targets fornew therapeutic agents for patients (Ko¨hrmann et al., 2009).
Two subclasses of MMPs viz. Gelatinases (MMP-2 and
MMP-9) and Collagenases (MMP-1 and MMP-13) are associ-
ated with breast tumor progression. Invasion and metastasis
are the most strenuous problems in the management of breast
cancer. These events require diverse proteolytic enzymes,
among which MMP-2 and MMP-9 play a signiﬁcant role in
degradation of type IV collagen, the major component of the
basement membrane (Shah et al., 2009). Elevated levels of
both MMP-2 and MMP-9 have been observed in blood from
breast cancer patients and were repeatedly found to be associ-
ated with advanced stage, lymph node metastasis, and poor
prognosis (Coskun et al., 2007; Farias et al., 2000; La Rocca
et al., 2004; Leppa et al., 2004; Liu et al., 2006; Quaranta
et al., 2007; Ranuncolo et al., 2003; Sheen-Chen et al., 2001;
Talvensaari-Mattila and Turpeenniemi-Hujanen, 2005; Zucker
et al., 1993, 1999). MMP-9 is abundantly expressed in various
malignant tumors and is postulated to play a critical role in tu-
mor invasion and angiogenesis (Chandler et al., 1997; Liabakk
et al., 1996). Matrix metalloproteinase-1 (MMP-1) and G
protein-coupled receptor, CXCR4 (Chemokine receptors),
are elevated in these activated ﬁbroblasts, in which they facil-
itate angiogenesis and matrix degradation, processes that are
also vital to breast cancer metastasis (Eck et al., 2009). Some
previous studies report also suggests a tumor-promoting role
for MMP-1 in breast cancer (Decock et al., 2008). MMP-13
protein was detected in the cytoplasm of carcinoma cells and
peritumoral ﬁbroblasts. High level expression of MMP-13 pro-
tein in tumor cells was associated with more lymph node
involvement and higher tumor grade. MMP-13 protein ex-
pressed by tumor cells correlates with the invasion and metas-
tasis of breast carcinoma, and therefore, may serve as a poor
prognostic marker for the patient (Zhang et al., 2008). Thus,
the inhibition of MMPs activity is important for the prevention
of cell invasion (Hidalgo and Eckhardt, 2001; Zhang et al., 2004).
Iridoids comprise part of a group of plant metabolites
based on a monoterpene structure with a cyclopenta[c]pyra-
noid skeleton. They are present in various medicinal plants
and are considered to be the active principles in some of them,
especially in Harpagophytum procumbens and Picrorhiza kurroa
(Ghisalberti, 1988). In the past few decades, several studies
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cal activity of this group of principles, but also in order to dem-
onstrate that they are indeed the active principles of the
medicinal plants that contain them. The most relevant effects
demonstrated by the different iridoids include cardiovascular,
anti-inﬂammatory, antitumoral, antiviral, and immunomodula-
tor activities, along with antihepatotoxic and antispasmodic ef-
fects. They also exhibit purgative, choleretic, hypoglycemic,
and hypolipidemic activities (Ghisalberti, 1988). The evidence
for the anti-inﬂammatory activity of iridoids was also present
in literature (Singh et al., 1993).
P. kurroa forms a major ingredient of many indigenous
medical preparations especially useful for the treatment of dis-
eases of liver, such as hepatitis (Mittal et al., 1978; Ansari
et al., 1988), jaundice (Handa et al., 1986), as well as anaemia
(Antarkar et al., 1988) and asthma (Langer et al., 1981). Previ-
ous studies report that P. kurroa shows anti-carcinogenic activ-
ity, anti-tumor activity (Joy et al., 2000) and also act on
hepatocarcinogenesis induced by N-nitrosodiethylamine (Jose
Jeena et al., 1999). However, there are no reports of its anti-
cancer activity against breast cancer and further there is no re-
port for the anticancer activity of iridoid glycosides viz.
Kutkin, Picroside I, Kutkoside. The aim of this work is to
study the cytotoxic activity of P. kurroa and the isolated irid-
oid glycosides viz. Kutkin, Picroside I, Kutkoside which are
present in this plant against breast cancer (MCF-7) cell lines,
down regulation of the MMPs, to check the migration and
invasion of MCF-7 cancer cells and to ﬁnd out the possible
anti-metastatic mechanism. (a): Picroside 1 2. Materials and methods
2.1. Chemicals
Cell lines were procured from National Center for Cell Sci-
ence, Pune, India. DMEM (Dulbecco’s Modiﬁed Eagle Med-
ium), MEM (Minimum Essential Medium), RPMI (Roswell
ParkMemorial Institute), L-glutamine, Penicillin, and Streptomycin
were procured from Himedia, Mumbai. FCS (Fetal Calf
Serum) was purchased from Lonza, Belgium. The following
chemicals were obtained from Sigma–Aldrich, USA: DMSO
(Dimethyl sulfoxide), HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid), Propidium iodide (PI). MTT
reagent [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide] Merck, India, Paclitaxel (Dabur, India), Kutkin,
Picroside I, Kutkoside (Rathee et al., manuscript no.;
(FILE#9079), Production tracking number: LJLC 551607)
were isolated in-house. All chemicals used were of analytical











Scheme 1 (a–c) Structures of Picroside I, Kutkoside and Kutkin.2.2. Instrumentation
ELISA plate reader (Bio Rad, USA), Polyvinylidene diﬂuoride
(PVDF) membrane ﬁlters (Millipore, Ireland), Rotary shaker
(R 100/TW Luckham, England), Microscope Olympus 1X51
with Prog Res Software (Jenoptix, Japan), Gel Doc System
(Bio Rad, USA), Gel assembly (BengloGenie, India). UV spec-
trophotometer (UV-2450 Shimadzu, Japan), Master cycler
gradient (Eppendorf, Germany), Lyophilizer (Allied frost
Lyophilizer, India), Deep freezer (Heto ultra freeze, UK).2.3. Extraction and isolation
2.3.1. Preparation of extract
Methanolic extract (PE) of P. kurroa was prepared by the fol-
lowing method: Accurately weighed 50 gm of the powdered
drug was extracted with methanol (100 mL · 4) under reﬂux
on a water bath. The extract was ﬁltered through a Whatman
I ﬁlter paper, pooled, and concentrated under vacuum to
dryness.
2.3.2. Isolation of active constituents
We isolated Kutkin (KS) (Scheme 1c), Picroside I (PS)
(Scheme 1a) and Kutkoside (KS) (Scheme 1b) using column
chromatography. The isolated compounds were characterized
by recording melting point using DSC, UV, IR, and Mass
spectra and identiﬁed by comparing with the reported data
(Singh et al., 1993).
2.4. Cell culture
MCF-7 human melanoma breast cancer cells were grown in
DMEM supplemented with 100 U/mL, Penicillin G, 100 lg/mL
Streptomycin, 0.25 lg/mL, Amphotericin, and 10% heat inac-
tivated fetal bovine serum. Cultures were maintained at 37 C
in a 5% CO2, 95% air atmosphere.
2.5. Cytotoxicity assays
Cytotoxicity screening models provide important preliminary
data to help in selecting plant extract with potential anti-
cancer properties for future work. Two cytotoxicity assays
were carried out on breast cancer cell lines.
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MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide] is taken up by the viable cells and reduced to formazan
by the ‘‘Succinate-tetrazolium reductase’’ system that belongs
to the mitochondrial respiratory chain functioning in metabol-
ically active cells. Formazan formed, is a purple colored water-
insoluble product that is largely impermeable to cell mem-
branes, thus resulting in its accumulation within the healthy
cells which is solubilized by adding DMSO. The optical density
(OD) of purple colored solution developed was read using a
conventional micro plate reader at 570 nm (maximum absor-
bance). The ability of cells to reduce MTT provides an indica-
tion of the mitochondrial integrity and activity, which, in turn,
may be interpreted as a measure of viability and/or cell num-
ber (Tripathi and Mait, 2005). Exponentially growing cancer
cells were harvested from 75 mm2 ﬂask (TPP, Switzerland)
and a stock cell suspension was prepared. 5 · 104 cells/mL
were seeded in a 96-well tissue culture plate with 200 lL of
DMEM and incubated for 24 h. The dry extract and the iso-
lated compounds (Kutkin, Picroside I and Kutkoside) were
dissolved in a minimum amount of DMSO and were prepared
in DMEM without phenol red. All the samples were ﬁrst ster-
ilized using PVDF membrane ﬁlters of 0.22 lm. Paclitaxel was
used as a positive control and was used at 1 lM, 5 lM concen-
trations. Cells were treated with different concentrations,
50 lg/mL and 100 lg/mL of PE and 5 lM, 10 lM of isolated
compounds (PS, KS, and KT) in 100 lL volume prepared in
media without phenol red and with a positive control and were
incubated for 48 h. The cells in the control group received no
drug treatment. Each treatment was performed in triplicates.
After the treatment, drug containing media was removed and
washed twice with 100 lL of PBS (Phosphate buffer saline).
To each well of the 96-well plate, 20 lL of MTT reagent
(Stock: 5 mg/mL) was added and incubated for 4 h at 37 C.
Plates were shaken for 10 min and inverted with gentle tapping
on tissue paper to remove the media. To solubilize formazan
crystals in the wells, 100 lL of 100% DMSO was added to
each well. Plates were placed on a Rotary shaker and agitated
for 15–20 min. The optical density was measured by an
Enzyme Linked Immunosorbent Assay (ELISA) plate reader
at 570 nm with a reference wavelength of 630 nm. O.D of each
well was read and expressed as percentage cell survival (absor-
bance of treated wells/absorbance of control wells · 100).
Results were expressed as Mean ± S.E. O.D values (propor-
tional to cell survival) was plotted against the extract concen-
trations. From the results, the active extract/s was considered
to be signiﬁcant which gave less than 50% survival at the expo-
sure time of 48 h. The PE was further diluted in medium to
produce 5 concentrations of 5, 25, 50, 75, and 100 lg/mL.
100 lL/well of each concentration was added to the plates in
triplicate and incubated for further 48 h. Its cytotoxic effect
was determined by MTT assay. The inhibitory concentration
IC50 of the crude extract was determined as the drug
concentration that decreased 50% of the O.D of the control
(untreated) cells.
2.5.2. Propidium iodide staining
PI binds to DNA by intercalating between the bases with little
or no sequence preference. Once the dye is bound to nucleic
acids, its ﬂuorescence is enhanced 20–30-fold. Propidium
iodide is suitable for ﬂuorescence microscopy, confocal laser
scanning microscopy, ﬂow cytometry, and ﬂuorometry. PI ismembrane impermeant and is generally excluded from viable
cells. PI is commonly used for identifying dead cells in a pop-
ulation and as a counterstain in multicolor ﬂuorescent tech-
niques. (According to the manufacturer’s protocol) Cells
(5 · 105 cells/mL) were cultured at 37 C for 3 days in medium
that contained 10% FBS. After 24 h media was aspirated.
Cells were treated with different concentrations, 50 lg/mL
and 100 lg/mL of the crude extract and 5 lM and 10 lM of
the isolated compounds in 100 lL volumes were prepared in
media without phenol red and were incubated for 48 h. The
cells in the control group received no drug treatment. At the
end of the treatment, the drug containing media was removed.
Cells were thoroughly washed 2–3 times with 3 mL of PBS to
remove any trace amount of drug and fresh 10% DMEM was
added. The cells were harvested, washed with PBS, ﬁxed with
75% ethanol at 4 C for 2 h, and treated with 0.25 mg/mL
RNAse (Sigma) at 37 C for 1 h. After washing, the cells were
stained with 500 lg/mL PI at room temperature for 10 min.
Digital images were taken under inverted ﬂuorescence micro-
scope, Olympus 1X51 with Prog Res Software from Jenoptix.
2.6. In vitro assays
2.6.1. Wound scratch migration assay
Cell migration is a complex phenomenon that requires the
coordination of numerous cellular processes. The commonly
used scratch wound healing assay of tissue-culture cell mono-
layers is by mechanically scratching the cell substrate with a
sterile plastic pipette tip, a characteristically sized wound is
created. Wound width is the measure of the distance covered
by the cells at different concentration after a particular time
point study. When wounded or scratched, the cell monolayer’s
respond to the disruption of cell–cell contacts and to growth
factors at the wound margin by healing the wound through
a combination of proliferation and migration. These processes
reﬂect the behavior of individual cells as well as the properties
of the cell sheet as a surrogate tissue. They have been used with
multiple cell types and, as the monolayer heals the wound in a
characteristic manner, used to study cell polarization, matrix
remodeling, cell migration, and numerous other processes.
A cell migration assay was performed using a 24-well plate
as previously described (Kim et al., 2003). 1 · 104 cells/mL
were seeded in 24-well plates, prepared in DMEM, and incu-
bated for 24 h. Cells were treated with different concentra-
tions, 50 lg/mL and 100 lg/mL of the crude extract and
5 lM and 10 lM of the isolated compounds in 100 lL volume
prepared in media without phenol red and with a positive con-
trol and were incubated for 48 h. The cells in the control group
received no drug treatment. At the end of the treatment, a
physical wound was given to all the plates in the presence of
drug containing media with a sterile plastic micro tip in a lin-
ear fashion throughout the center of the plate. This media was
removed and the cells were thoroughly washed 2–3 times with
2 mL of PBS to remove any trace amount of drug and the dis-
lodged cells. One of the plates was immediately ﬁxed in meth-
anol. The rest of the plates were incubated with freshly
prepared 10% DMEM for 24 h. After incubation, media was
aspirated out; cells were washed twice with 2 mL of PBS, ﬁxed
with 75% ethanol at 4 C for 2 h. After washing, the cells were
stained with 500 lg/mL of dye at room temperature for
10 min. Digital images were obtained with an inverted ﬂuores-
cence microscope.
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Zymography is anelectrophoreticmethodbasedon sodiumdode-
cyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) for
measuring activity of proteolytic enzymes. The gel is impregnated
with a protein substrate depending on the activity of the enzyme
to be studied (e.g. type III gelatin) that is commonly chosen for
studying gelatinases. Gelatin is degraded by the proteases re-
solved during the incubation period (conditioned media). Sam-
ples for Zymography are prepared in the standard SDS–PAGE
treatment buffer but without boiling, and without a reducing
agent (b-mercaptoethanol). Following electrophoresis, the SDS
is removed from the gel (or Zymogram) by incubation in 2.5%
Triton X-100. Staining the gel with Coomassie (Sigma) and
destaining with 40%methanol, 10% acetic acid allows the bands
ofproteolytic activity tobedetected as clear bands of lyses against
a blue background.Within a certain range, the band intensity can
be related linearly to the amountofprotease loaded (Hauzenberger
et al., 1999).
In 6-well plates, 3 · 104 cells/mL prepared in 10% DMEM
were seeded and incubated for 24 h. Cells were treated with dif-
ferent concentrations, 50 lg/mL and 100 lg/mL of the crude
extract and 5 lM and 10 lM of the isolated compounds in
100 lL volume were prepared in media without phenol red
and with a positive control and were incubated for 48 h. The
cells in the control group received no drug treatment. At the
end of the treatment, the drug containing media was removed
and the cells were thoroughly washed twice with 2 mL of PBS
to remove any trace amount of drug. To the culture plate 2 mL
of plain DMEM was added (without supplemented with 10%
FBS) and incubated for 18–20 h. After incubation, the serum
free media called as the conditioned media was centrifuged
at 1400 rpm for 10 min to remove any cell debris. The cells
in the culture were trypsinized, except that no extra fresh med-
ia was added to stop the trypsin activity instead the media col-
lected from the culture plate itself was added. The conditioned
media was concentrated by lyophilization and protein content
estimated by Folin Lowry method, and stored at 80 C until
further use. The conditioned media was reconstituted using
autoclaved water and to assess the gelatinase activity, samples
(110 lL for 24 h and 150 lL for 48 h) were run on 10% (w/v)
SDS–PAGE with certain modiﬁcations containing 2% (w/v)
gelatin. Proteinase K (Sigma) served as a positive control.
The gel apparatus was set up on a vertical mini gel assemblyFigure 1 Cytotoxicity activity was evaluated by MTT assay. Cells w
and KT each and positive control (Paclitaxel – 1 and 5 lM) for 48 h, th
viability on MCF-7 human breast cancer cell line was calculated. Con.
Picroside I; KS – Kutkoside; KT – Kutkin.and the bottom was sealed with 0.8% agarose (HiMedia).
Finally, the MMP gel was stained for 30 min with 0.25%
(w/v) Coomassie blue in 10% acetic acid (v/v) and 50%
methanol (v/v) and destained in 10% acetic acid (v/v) and
50% methanol (v/v). Gel documentation software was used
and the images were taken.
2.6.3. Semiquantitative RT-PCR (mRNA analysis)
To check the mRNA expression of these proteases, cancer cells
(2 · 106 cells/mL) were treated with PE and PS, KS and KT for
18 h. The total RNA was isolated using TRIzol RNA Extrac-
tion Kit in accordance with the manufacturer’s instructions.
Complementary DNA was synthesized from 1 lg of total
RNA in a 20 lL reverse transcription reaction mixture. For
semiquantitative PCR, aliquots of cDNA were ampliﬁed in a
25 lL PCR mixture as described previously (Zhang et al.,
2004). The PCR products were size-fractionated and DNA
bands were visualized by staining the gel with ethidium
bromide. b-actin primers were used as normalization control.
PCR was performed in the presence of 0.5 U Taq DNA poly-
merase (Takara, Japan) using primer sets that were speciﬁc to
the following: human MMP-2 (50-GTG CTG AAG GAC
ACA CTA AAG AAG A-30, 30-GGA TGT TGA AAC TCT
TCC TAC CGT T-50); MMP-9 (50-CAC TGT CCA CCC
CTC AGA GC-30, 30-GGA ATA GCG GCT GTT CAC CG-
50); MMP-1 (50-CCT TCT ACC CGG AAG TTG AG-30, 50-
TCC GTG TAG CAC ATT CTG TC-3); MMP-13 (50-GTG
GTG TGG GAA GTA TCA TCA-30, 50-GCA TCT GGA
GTA ACC GTA TTG-30); b-actin (50-TGT GAT GGT GGG
AAT GGG TCA G-30, 50-TTT GAT GTC ACG CAC GAT
TTC C-30). The PCR products were separated on a 2% agarose
gel containing ethidium bromide (0.5 lg/mL), visualized, and
photographed using a gel documentation system.3. Results
3.1. Cytotoxic effect of PE and iridoid glycosides PS, KS and
KT
Initially, we measured the cytotoxicity of PE to MCF-7 cells by
MTT and PI assays. Dose-dependent cytotoxic effect of PE
against MCF-7 cells was shown in Fig. 1. IC50 value of theere treated with 50 and 100 lg/mL of PE, 5 and 10 lM of PS, KS
ereafter cultures were evaluated as described in text. Percentage cell
– control; Pac. – Paclitaxel; PE – Picrorrhiza kurroa extract; PS –
Figure 3 Effect of PE and PS, KS and KT on MCF-7 (breast cance
was evaluated by wound scratch migration assay. (A) Control; (B) P
(5 lM); (E) Kutkoside (5 lM); (F) Kutkin (5 lM).
Table 1 Cytotoxicity of methanolic extract of Picrorrhiza
kurroa rhizomes on MCF-7 human cancer cell lines at various
concentrations. IC50 for PE was found to be 61.86.
Concentration (lg/mL) % Cell viabilitya
MCF-7
5 84.40 ± 1.05
25 73.79 ± 0.41
50 61.86 ± 0.91
75 54.26 ± 0.75
100 41.80 ± 0.32
Figure 2 Effect of PE and PS, KS and KT on MCF-7 (breast cancer
evaluated by Propidium iodide staining. (A) Control; (B) PE conc. 1 (5
(E) Kutkoside (KS) (5 lM); (F) Kutkin (KT) (5 lM).
54 D. Rathee et al.PE was found to be 61.86 (Table 1). PE among the 5 tested
concentrations of 5, 25, 50, 75, and 100 lg/mL, did not signif-
icantly affect the cytotoxicity at the conc. 5 and 25 lg/mL, but
at 75 and 100 lg/mL concentration it showed 95% cell viabil-
ity. Thus, we treated cells with PE in the concentration of
50 lg/mL and 100 lg/mL during subsequent experiments.
Investigation of the cytotoxicity by PI assay which is mem-
brane impermeable and is generally excluded from viable cells.
Results (Fig. 2) showed that the viable cells did not take the PI
while the cells treated with PE extensively taken up the stain,
which conﬁrms its cytotoxic potential. Further on comparison
of the cytotoxicity of the PS, KS, and KT isolated from P. kurroar) cell line. Treated cell were incubated for 48 h and cell migration
E conc. 1 (50 lg/ml); (C) PE conc. 2 (100 lg/ml); (D) Picroside I
) cell line. Treated cell were incubated for 48 h and cell death was
0 lg/ml); (C) PE conc. 2 (100 lg/ml); (D) Picroside I (PS) (5 lM);
Table 2 Comparision of cytotoxicity of Picrorrhiza kurroa
extract and its isolated compounds on MCF-7 human cancer
cell line (breast cancer).
Sample Concentration % Cell viabilitya
MCF-7
Paclitaxel (1 lM) 46.63 ± 2.84
(5 lM) 43.96 ± 2.49
Picrorrhiza kurroa Rhizomes (50 lg/mL) 61.86 ± 0.92
(100 lg/mL) 41.80 ± 0.32
Picroside I (5 lM) 39.21 ± 2.48
(10 lM) 25.53 ± 0.74
Kutkoside (5 lM) 42.60 ± 3.78
(10 lM) 28.23 ± 2.97
Kutkin (5 lM) 37.85 ± 1.65
(10 lM) 25.98 ± 3.25
a Mean ± S.D. (n= 3).
Iridoid glycosides-Kutkin, Picroside I, and Kutkoside from Picrorrhiza kurroa 55on MCF-7 cells with that of the PE, results showed that the
pure compounds exhibits signiﬁcant cytotoxicity as compared
to the PE. Among PS, KS, and KT, the compound KT showed
higher cytotoxicity in both of the cytotoxicity assays, while the
compounds PS and KS exhibit almost equivalent activity (Ta-
ble 1, Fig. 1). The data showed that the activity of PS, KS, and
KT was found to be comparable to that of positive control
paclitaxel on MCF-7 cells. On the basis of these results P. kurroa
and its iridoid glycosides were selected for further studies. To
investigate whether PE and iridoid glycosides PS, KS, and
KT inhibits tumor invasion and migration, wound migration,
gelatin zymography, and RT-PCR assays were performed in
PE and PS, KS, and KT-treated MCF-7 cells. The invasiveness
of serum-induced MCF-7 cells was signiﬁcantly increased,
compared to untreated cells, as determined with the wound
scratch migration invasion assay (data not shown). Treatment
with 50 and 100 lg/mL of PE reduced the invasiveness of cells
induced by serum in a dose dependant manner, while com-
pounds PS, KS, and KT in 5 lM and 10 lM signiﬁcantly
blocked tumor invasion. Furthermore the compound KT
showed to inhibit the invasion and migration of MCF-7 cells
more considerably than KS and PS. In addition, PS, KS,
and KT suppressed the migration of MCF-7 cells across the
wounded space in a time and dose dependant manner
(Fig. 3). These results suggest that the PE and compounds
PS, KS, and KT may be used for suppressing MCF-7 cell
metastasis and migration (see Table 2).Figure 4 Effect of PE and PS, KS, and KT on MCF-7 (breast canc
activity was evaluated by Gelatin Zymography. (1) Control; (2) Prote
Picroside I (5 lM); (6) Kutkoside (5 lM); (7) Kutkin (5 lM).3.2. Effect of PE and iridoid glycosides PS, KS and KT on the
activity of MMPs
Invasion of cancer cells in the extracellular matrix requires
MMPs activity. To determine whether PE and isolated com-
pounds directly inhibits MMPs activity, we performed the
zymographic analysis and it revealed that MMPs proteins were
constitutively expressed in untreated MCF-7 cells. Zymo-
graphic evaluation was performed on supernatants of the
MCF-7 cultures treated with 50 lg/mL and 100 lg/mL PE
and 5 lM conc. of the compounds PS, KS, and KT.
Conditioned medium of the MCF-7 cells contained an activity
corresponding to gelatinases (MMP-2, -9) and collagenases
(MMP-1, -13) (Fig. 4). Less difference in MMPs gelatinase
activity was observed after treatment with PE compared to
the solvent-treated cells. We further examined whether isolated
compounds PS, KS, and KT could suppress MMPs expression
and the invasion of breast cancer cells. In contrast, MMPs re-
lease was reduced in the supernatants of cells treated with PS,
KS, and KT and interestingly the isolated compounds exhibit
the comparable down-regulation of MMPs expression. Our re-
sults from zymogram gels indicated that PS, KS, and KT
potentially blocked MMPs expression in human breast cancer
MCF-7 cells at a concentration of 5 lM. These results sug-
gested that PS, KS, and KT could play a crucial role in the
down regulation of MMPs expression. (Fig. 4A and B)
3.3. Effects of PE and iridoid glycosides PS, KS and KT on the
activities and expressions of MMPs
Because MMP-2, MMP-9, MMP-1, and MMP-13 have been
indicated to be associated with cancer invasion, we, therefore,
investigated whether these molecules were involved in PE and
isolated compounds PS, KS. and KT mediated invasion down-
regulation. We conﬁrmed the inhibition of PE and isolated
compounds PS, KS, and KT on MMPs activity by RT-PCR
(m-RNA analysis). Next, we measured the expression levels
of MMPs to examine whether reduced MMPs activities were
due to changes in their protein and gene levels or in the levels
of other regulatory molecules involved in the activation pro-
cess. We found that PS, KS, and KT signiﬁcantly inhibited gel-
atinases MMP-1,-9 and collagenases MMP-1, -13 activity in
MCF-7cells, while the PE showed less inhibition of MMPs
expression as compared with the isolated compounds. PS,
KS, and KT and suppressed the expression of MMP proteiner) cell line. Treated cell were incubated for 72 h and Gelatinase
inase K; (3) PE conc. 1 (50 lg/ml); (4) PE conc. 2 (100 lg/ml); (5)
Figure 5 Relative mRNA expression of gelatinases MMPs shows a down regulation in collagen degrading enzymes upon treatment. (1)
Control; (2) PE conc. 1 (50 lg/ml); (3) PE conc. 2 (100 lg/ml); (4) Picroside I (5 lM); (5) Kutkoside (5 lM); (6) Kutkin (5 lM).
Figure 6 Relative mRNA expression of collagenases MMPs shows a down regulation in collagen degrading enzymes upon treatment. (1)
Control; (2) PE conc. 1 (50 lg/ml); (3) PE conc. 2 (100 lg/ml); (4) Picroside I (5 lM); (5) Kutkoside (5 lM); (6) Kutkin (5 lM).
56 D. Rathee et al.and mRNA levels (Figs. 5 and 6) which forms a speciﬁc com-
plex with the MMPs and thus inhibits the activation of MMPs.
Additionally, PS, KS, and KT suppressed MMPs transcrip-
tional activity in a dose dependent manner. This indicated that
isolated compounds PS, KS, and KT have the tendency to in-
hibit the metastasis of cancer.
4. Discussion
Invasion and metastasis are fundamental properties of malig-
nant cancer cells. In multiple steps of these processes, degrada-
tion of environmental barriers such as ECM and basement
membrane is the initial step, and a number of proteolytic en-
zymes participate in degrading these barriers (Woessner,
1991). Among these enzymes, MMPs play major roles. Espe-
cially, MMP-2 (gelatinase A) and -9 (gelatinase B) degrades
type IV collagen constituting the major structural component
of the basement membrane and ECM, and they are believed
to be crucial in the invasion of malignant tumors (Aimes and
Quigley, 1995; Kleiner and Stetler-Stevenson, 1993). The activ-
ity of MMP-2 and -9 is often found to be elevated in tumor tis-
sues and malignant cells (Dredge et al., 2003). MMP-2 and -9
have been implicated as playing an important role in cancer
invasion and metastasis (Levy et al., 1991; Librach et al.,
1991). Invasion is a characteristic feature of carcinoma, which
frequently shows early invasion into blood vessels as well as
tumor metastasis, which occurs subsequently (Pasco et al.,
2005). Thus, the discovery of novel natural products and their
components to block cancer invasion and migration are the
goals of cancer researchers. Anticancer properties have been
associated with the components of various natural products
including green tea polyphenols, resveratrol, limonene, and
organosulfur compounds from garlic (Kaegi, 1998). Especially,
baicalein and baicalin inhibited migration of the human vascu-
lar endothelial cells in a dose-dependent manner (Liu et al.,
2003). Green tea polyphenols and one of its constituents
(epigallocatechin gallate) caused a strong inhibition of the gel-
atinolytic activity of MMP-9 and the secretion of MMP-2
(Demeule et al., 2000; Annabi et al., 2002).
In the present study, the methanolic extract of P. kurroa
and its isolated compounds KT, PS, and KS were analyzedthe effect on MMP-2, -9, and MMP-1, -13 activities. PE and
isolated compounds KT, PS, and KS showed a signiﬁcant
inhibitory activity on both classes of MMPs, and the IC50
for PE from the cytotoxicity was found to be 61.86. Among
the compounds KT showed a signiﬁcant inhibitory activity
on MMPs, at a concentration of 5 lM. In addition, PE has
good cytotoxic activity on MCF-7 cells, PE signiﬁcantly inhib-
ited the invasion of MCF-7 cells at the concentration of
100 lg/mL. In conclusion, these results suggested that PE
has anti-invasive and anti-metalloproteinase activity, and PS,
KS, and KT are the major players of the inhibitory potential.
The results may serve as a leader compound with the develop-
ment of anti-tumor drugs.
In conclusion, our data strongly imply that PE and PS, KS,
and KT inhibit tumor invasion and migration. Firstly, by
inhibiting the migration of MCF-7 cells. Secondly, by sup-
pressing both classes of MMPs at proteins and mRNA levels
and considerable down regulation of both the subclasses of
MMPs was exhibited by all of the PS, KS, and KT These stud-
ies provide important information about the antiinvasive and
antimetastatic nature of PS, KS, and KT prospecting these
candidates for developing into potential anticancer therapeu-
tics and also have potential avenues for targeting the spread
of cancer. We here report that PE and its isolated iridoids com-
pounds PS, KS, and KT inhibited invasion- or metastasis-asso-
ciated protease activities. The inhibition was also related to the
suppression of transcriptional level; however, its mechanism of
action still remains elusive. In addition, all three isolated com-
pounds inhibit degradation and cellular invasion of ECM and
basement membrane. This study provides an additional activ-
ity of the antimetastatic potential beyond antitumor activity
mediated by PE and PS, KS and KT.Acknowledgments
We thank Prof. Harish Padh, Project Director, NIPER-
Ahmedabad for providing the funds and facilities for the
completion of this work. Authors are also thankful to the un-
known reviewers for their critical evaluation of the manuscript,
for enhancement.
Iridoid glycosides-Kutkin, Picroside I, and Kutkoside from Picrorrhiza kurroa 57References
Aimes, R.T., Quigley, J.P., 1995. Matrix metalloproteinase-2 is an
interstitial collagenase. J. Biol. Chem. 270, 5872–5876.
Annabi, B., Lachambre, M.P., Bousquet-Gagnon, N., Page, M.,
Gingras, D., Beliveau, R., 2002. Green tea polyphenol ()-
epigallocatechin 3-gallate inhibits MMP-2 secretion and MT1-
MMP-driven migration in glioblastoma cells. Biochim. Biophys.
Acta 1542, 209–220.
Ansari, R.A., Aswal, B.S., Chander, R., Dhawan, B.N., Sharma, S.K.,
1988. Hepatoprotective activity of Kutkin, the iridoid glycoside
mixture of Picrorrhiza kurroa. Indian J. Med. Res. 87, 401–404.
Antarkar, D.S., Vaidya, A.B., Doshi, J.C., Ramesh, V., Kale, N.,
1988. A double blind clinical trial of Arogyawardhani, an Indian
drug in acute viral hepatitis. Indian J. Med. Res. 72, 588–593.
Bange, J., Zwick, E., Ullrich, A., 2001. Molecular targets for breast
cancer therapy and prevention. Nat. Med. 7, 548–552.
Bhowmick, N.A., Neilson, E.G., Moses, H.L., 2004. Stromal ﬁbro-
blasts in cancer initiation and progression. Nature 432, 332–337.
Chandler, S., Miller, K.M., Clements, J.M., Lury, J., Corkill, D.,
Anthony, D.C., 1997. Matrix metalloproteinases, tumor necrosis
factor and multiple sclerosis: an overview. J. Neuroimmunol. 72,
155–161.
Colomer, R., Shamon, L.A., Tsai, M.S., Lupu, R., 2001. Herceptin:
from the bench to the clinic. Cancer Invest. 19, 49–56.
Coskun, U., Yamac, D., Gulbahar, O., Sancak, B., Karaman, N.,
Ozkan, S., 2007. Locally advanced breast carcinoma treated with
neoadjuvant chemotherapy: are the changes in serum levels of
YKL-40, MMP-2 and MMP-9 correlated with tumor response?
Neoplasma 54, 348–352.
De Wever, O., Mareel, M., 2002. Role of myoﬁbroblasts at the
invasion front. Biol. Chem. 383, 55–67.
De Wever, O., Mareel, M., 2003. Role of tissue stroma in cancer cell
invasion. J. Pathol. 200, 429–447.
Decock, J., Hendrickx, W., Vanleeuw, U., Van Belle, V., Van Huffel,
S., Christiaens, M.R., Ye, S., Paridaens, R., 2008. Plasma MMP1
and MMP8 expression in breast cancer: protective role of MMP8
against lymph node metastasis. BMC Cancer 20, 8–77.
Demeule, M., Brossard, M., Page, M., Gingras, D., Beliveau, R., 2000.
Matrix metalloproteinase inhibition by green tea catechins. Bio-
chim. Biophys. Acta 1478, 51–60.
Desmoulie`re, A., Guyot, C., Gabbiani, G., 2004. The stroma reaction
myoﬁbroblast: a key player in the control of tumor cell behaviour.
Int. J. Dev. Biol. 48, 509–517.
Dolle´, L., Adriaenssens, E., El Yazidi-Belkoura, I., Le Bourhis, X.,
Nurcombe, V., Hondermarck, H., 2004. Nerve growth factor
receptors and signaling in breast cancer. Curr. Cancer Drug
Targets 4, 463–470.
Dredge, K., Dalgleish, A.G., Mariott, J.B., 2003. Angiogenesis
inhibitors in cancer therapy. Curr. Opin. Investig. Drugs 4, 667–
674.
Duffy, M.J., Maguire, T.M., Hill, A., McDermott, E., O’Higgins, N.,
2000. Metalloproteinases: role in breast carcinogenesis, invasion
and metastasis. Breast Cancer Res. 2 (4), 252–257.
Eck, S.M., Coˆte´, A.L., Winkelman, W.D., Brinckerhoff, C.E., 2009.
CXCR4 and matrix metalloproteinase-1 are elevated in breast
carcinoma-associated ﬁbroblasts and in normal mammary ﬁbro-
blasts exposed to factors secreted by breast cancer cells. Mol.
Cancer Res. 7 (7), 1033–1044.
Egeblad, M., Werb, Z., 2002. New functions for the matrix metallo-
proteinases in cancer progression. Nat. Rev. Cancer 2, 161–
174.
Farias, E., Ranuncolo, S., Cresta, C., Specterman, S., Armanasco, E.,
Varela, M., Lastiri, J., Pallotta, M.G., Bal De Kier, J.E., Puricelli,
L., 2000. Plasma metalloproteinase activity is enhanced in the
euglobulin fraction of breast and lung cancer patients. Int. J.
Cancer 89, 389–394.Forrbes, K., Gillette, K., Sehgal, I., 2003. Lycopene increases
urokinase receptor and fails to inhibit growth or connexin
expression in a metastatically passaged prostate cancer cell line: a
brief communication. Exp. Biol. Med. 228, 967–971.
Ghisalberti, E.L., 1988. Biological and pharmacological activity of
naturally occurring iridoids and secoiridoids. Phytomedicine 5,
147–163.
Guo, W., Giancotti, F.G., 2004. Integrin signaling during tumor
progression. Nat. Rev. Mol. Cell Biol. 5, 816–826.
Handa, S.S., Sharma, A., Chakraborthi, K.K., 1986. Natural products
and plants as liver protecting drugs. Fitoterapia 58, 307–351.
Hauzenberger, D., Bergstrom, S.E., Klominek, J., Sundqvist, K.G.,
1999. Spectrum of extracellular matrix degrading enzyme in normal
and malignant T lymphocytes. Anticancer Res. 90, 65–78.
Hidalgo, M., Eckhardt, S.G., 2001. Development of matrix metallo-
proteinase inhibitors in cancer therapy. J. Nat. Cancer Inst. 93,
178–193.
Jose Jeena, K., Joy, K.L., Kuttan, R., 1999. Effect of Emblica
ofﬁcinalis, Phyllanthus amarus and Picrorrhiza kurroa on N-
nitrosodiethylamine induced hepatocarcinogenesis. Cancer Lett.
136, 11–16.
Joy, K.L., Rajeshkumar, N.V., Kuttan, G., Kuttan, R., 2000. Effect of
Picrorrhiza kurroa extract on transplanted tumours and chemical
carcinogenesis in mice. J. Ethnopharmacol. 71, 261–266.
Joyce, J.A., 2005. Therapeutic targeting of the tumor microenviron-
ment. Cancer Cell 7, 513–520.
Kaegi, E., 1998. Unconventional therapies for cancer: 2. Green tea.
The task force on alternative therapies of the Canadian breast
cancer research initiative. Can Med. Assoc. J. 158, 1033–1035.
Kim, M.S., Lee, E.J., Choi, H.R., Moon, A., 2003. p38 kinase is a key
signaling molecule for H-Ras-induced cell motility and invasive
phenotype in human breast cancer cells. Cancer Res. 63, 5454–
5461.
Kleiner, D.E., Stetler-Stevenson, W.G., 1993. Structural biochemistry
and activation of matrix metalloproteinases. Curr. Opin. Cell Biol.
5, 891–897.
Ko¨hrmann, A., Kammerer, U., Kapp, M., Dietl, J., Anacker, J., 2009.
Expression of matrix metalloproteinases (MMPs) in primary
human breast cancer and breast cancer cell lines: New ﬁndings
and review of the literature. BMC Cancer 9, 188.
La Rocca, G., Pucci-Minafra, I., Marrazzo, A., Taormina, P.,
Minafra, S., 2004. Zymographic detection and clinical correlations
of MMP-2 and MMP-9 in breast cancer sera. Br. J. Cancer 90,
1414–1421.
Langer, L.G., Gupta, O.P., Atal, C.K., 1981. Clinical trials of
Picrorrhiza kurroa as immunomodulator. Indian J. Pharmacol.
13, 98–99.
Leppa, S., Saarto, T., Vehmanen, L., Blomqvist, C., Elomaa, I., 2004.
A high serum matrix metalloproteinase-2 level is associated with an
adverse prognosis in node-positive breast carcinoma. Clin. Cancer
Res. 10, 1057–1063.
Levy, A.T., Cioce, V., Sobel, M.E., Garbisa, S., Grigioni, W., Liotta,
L.A., 1991. Increased expression of the 72 kDa type IV collagenase
in human colonic adenocarcinoma. Cancer Res. 51, 439–444.
Liabakk, N.B., Talbot, I., Smith, R.A., Wilkinson, K., Balkwill, F.,
1996. Matrix metalloprotease 2 (MMP-2) and matrix metallopro-
tease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer
Res. 56, 190–196.
Librach, C.L., Werb, Z., Fitzgerald, M.L., Chiu, K., Corwin, N.M.,
Esteves, R.A., 1991. 92-kD type IV collagenase mediates invasion
of human cytotrophoblasts. J. Cell Biol. 113, 437–449.
Liotta, L.A., Kohn, E., 2001. The microenvironment of the tumor-host
interface. Nature 430, 973–974.
Liu, S.C., Yang, S.F., Yeh, K.T., Yeh, C.M., Chiou, H.L., Lee, C.Y.,
Chou, M.C., Hsieh, Y.S., 2006. Relationships between the level of
matrix metalloproteinase-2 and tumor size of breast cancer. Clin.
Chim. Acta 371, 92–96.
58 D. Rathee et al.Liu, J.J., Huang, T.S., Cheng, W.F., Lu, F.J., 2003. Baicalein and
baicalin are potent inhibitors of angiogenesis: inhibition of endo-
thelial cell proliferation. Int. J. Cancer 106, 559–565.
Mittal, G.C., Saxena, S., Kanchan, S.K., Mangal, O.P., Dandiya, P.C.,
1978. Clinical trials on bibarin in liver disorders with special
reference to infective hepatitis. Indian Pract. August, 683–693.
Parmo-Cabanas, M., Molina-Ortiz, I., Matias-Roman, S., Garcia-
Bernal, D., Carvajal-Vergara, X., Valle, I., 2006. Role of metallo-
proteinases MMP-9 and MT1-MMP in CXCL12-promoted mye-
loma cell invasion across basement membranes. J. Pathol. 208,
108–118.
Pasco, S., Brassart, B., Ramont, L., Maquart, F.X., Monboisse, J.C.,
2005. Control of melanoma cell invasion by type IV collagen.
Cancer Detect. Prev. 29, 260–266.
Quaranta, M., Daniele, A., Coviello, M., Venneri, M.T., Abbate, I.,
Caringella, M.E., Di, T.S., Divella, R., Trerotoli, P., Di, G.M.,
Schittulli, F., Fransvea, E., Giannelli, G., 2007. MMP-2, MMP-9,
VEGF and CA 15.3 in breast cancer. Anticancer Res. 27, 3593–
3600.
Ranuncolo, S.M., Armanasco, E., Cresta, C., Bal De Kier, J.E.,
Puricelli, L., 2003. Plasma MMP-9 (92 kDa-MMP) activity is
useful in the follow up and in the assessment of prognosis in breast
cancer patients. Int. J. Cancer 106, 745–751.
Rathee, D., Thanki, M., Agarwal, R., Anandjiwala, S., 2011. Isolation,
Characterization and Simultaneous Quantiﬁcation of Picroside I
and Kutkoside using HPTLC from Picrorrhiza kurroa Benth.
Journal of liquid chromatography and related technologies, as
accepted manuscript no.; (FILE#9079), Production tracking num-
ber: LJLC 551607.
Shah, F.D., Shukla, S.N., Shah, P.M., Shukla, H.K., Patel, P.S., 2009.
Clinical signiﬁcance of matrix metalloproteinase 2 and 9 in breast
cancer. Indian J. Cancer 46, 194–202.
Sheen-Chen, S.M., Chen, H.S., Eng, H.L., Sheen, C.C., Chen, W.J.,
2001. Serum levels of matrix metalloproteinase 2 in patients with
breast cancer. Cancer Lett. 173, 79–82.Singh, G.B., Bani, S., Singh, S., Khajuria, A., Sharma, M.L., Gupta,
B.D., Banerjee, S.K., 1993. Antiinﬂammatory activity of the
iridoids Kutkin, Picroside-1 and Kutkoside from Picrorhiza kurroa.
Phytother. Res. 7, 402–407.
Talvensaari-Mattila, A., Turpeenniemi-Hujanen, T., 2005. Preopera-
tive serum MMP-9 immunoreactive protein is a prognostic
indicator for relapse-free survival in breast carcinoma. Cancer
Lett. 217, 237–242.
Tripathi, S., Mait, T.K., 2005. Immunomodulatory role of native and
heat denatured agglutinin from Abrus precatorius. Int. J. Biochem.
Cell Biol. 37, 451–462.
Woessner Jr., J.F., 1991. Matrix metalloproteinases and their inhib-
itors in connective tissue remodeling. FASEB J. 5, 2145–2154.
Xiao, T., Takagi, J., Coller, B.S., Wang, J.H., Springer, T.A., 2004.
Structural basis for allostery in integrins and binding to ﬁbrinog-
enmimetic therapeutics. Nature 432, 59–67.
Yana, I., Seiki, M., 2002. MT-MMPs play pivotal roles in cancer
dissemination. Clin. Exp. Metastasis 19, 209–215.
Zhang, B., Liu, Y.X., Cao, W.F., Cao, X.C., Ning, L.S., Hao, X.S.,
2008. Relationship between the expression of matrix metallopro-
teinase-13 protein and other biomarkers, prognosis in invasive
breast cancer. Zhonghua Bing Li Xue Za Zhi 37, 471–476.
Zhang, M., Altuwaijri, S., Yeh, S., 2004. RRR-alpha-tocopheryl
succinate inhibits human prostate cancer cell invasiveness. Onco-
gene 23, 3080–3088.
Ziche, M., Donnini, S., Morbidelli, L., 2004. Development of new
drugs in angiogenesis. Curr. Drug Targets 5, 389–406.
Zucker, S., Lysik, R.M., Zarrabi, M.H., Moll, U., 1993. M(r) 92,000
type IV collagenase is increased in plasma of patients with colon
cancer and breast cancer. Cancer Res. 53, 140–146.
Zucker, S., Hymowitz, M., Conner, C., Zarrabi, HM., Hurewitz, AN.,
Matrisian, L., Boyd, D., Nicolson, G., Montana, S., 1999.
Measurement of matrix metalloproteinases and tissue inhibitors
of metalloproteinases in blood and tissues. Clin. Exp. Appl. Annu.
N Y Acad. Sci. 878, 212–227.
